Navigation Links
Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
Date:3/7/2011

which include costs of POS and TOS, R&D and G&A were $7,742,000 compared to $5,369,000 for the comparable period last year, an increase of $2,373,000, or 44%.  Interest and other income for the nine months ended January 31, 2011 was $1,344,000.  The Company reported a net loss of $1,060,000, or ($0.03) per share, as compared to a net loss of $2,371,000, or ($0.07) per share, for the comparable period in fiscal 2010.

Joel Ackerman, the Company's Chief Executive Officer, commented, "The financial growth we achieved this quarter is a clear indication of the need for personalized oncology products for both physicians and medical technology companies.  The foundation that was built over the last three years, combined with the sales resources we are adding, is beginning to result in an increased momentum for our Company."

* Non-GAAP Financial InformationSee the attached Reconciliation of GAAP Net Loss to Non-GAAP Net Income (Loss) for an explanation of the amounts excluded to arrive at non-GAAP net income (loss) and related non-GAAP earnings (loss) per share amounts for the three months ended January 31, 2011 and 2010, respectively.  Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis.  Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items.  Non-GAAP net income (loss) and non-GAAP earnings (loss) per share are not, and should not be viewed as a substitute for similar GAAP items.  We define non-GAAP diluted earnings per share amounts as non-GAAP net income divided by the weighted average number of diluted shares outstanding.  Our definition of non-GAAP net income (loss) and non-GAAP diluted ea
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Additions to its Management Team
2. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
3. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
4. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
7. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
8. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
9. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
10. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
11. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015  Schulman Associates IRB, Inc., the industry-leading ... a long-term lease on Laboratory Drive in the heart ... . The location will house review board and service ... quality reviews and customer service to clients. ... Schulman in the deal, while Capital Associates Management, LLC ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... - Portage Biotech Inc. ("Portage" or "the Company" )) ... to announce that the Company will be presenting  at ... be held in London, UK . ... James Mellon , a director of Portage, will ... programs at its subsidiaries, Portage Pharmaceuticals Ltd. ("PPL"), and ...
(Date:4/16/2015)... , April 16, 2015 ... the Russian pharmaceutical investment and R&D group, ... collaboration for research, development and commercialization of ... with the intention to stimulate the ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: ...
Breaking Biology Technology:Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2
... 5:00 p.m. U.S. ET - EXTON, ... ) today announced that it will hold a conference call ... discuss fourth quarter and year end financials and an update ... portion and have the opportunity to pose questions, dial (866) ...
... ,Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the ... release its financial,results for the full year 2008 on ... (CET). To discuss these results, the Company will,conduct a ... The dial-in number for the ...
... Pa., Feb. 18 Jennifer Brownstein, Art ... named a 2009 Rising Star by the ... are up-and-coming professionals in various sectors of ... public relations, medical education, and market research. ...
Cached Biology Technology:Adolor Corporation to Host Investor Conference Call to Report 2008 Financials and Provide an Update on the Launch of ENTEREG(R) (alvimopan) 2AMT to Release Full Year 2008 Results on February 24, 2009 2Jennifer Brownstein, of CONNEXION Healthcare, Honored as 'Rising Star' by Healthcare Businesswomen's Association 2
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... MIT engineers have outfitted cells with tiny "backpacks" that could ... building blocks for tissue engineering. Michael Rubner, director of ... of a paper on the work that appeared online in ... this is the first time anyone has attached such a ...
... Nov. 6, 2008 -- Billions of tons of carbon sequestered ... atmosphere in the coming decades as a result of global ... peat bogs, water tables, and climate change. Such an ... locked away in the world,s peat bogs would dwarf emissions ...
... study highlights the role of a charge-switching enzyme in ... related neurological illness. Multiple sclerosis (MS) is ... insulator for electrical signaling in the nervous system ... nerve function. Much like the rubber insulation on ...
Cached Biology News:MIT creates tiny backpacks for cells 2Global warming predicted to hasten carbon release from peat bogs 2Multiple sclerosis research charges ahead with new mouse model of disease 2
Recombinant Rhesus Monkey IFN Alpha Activity: 2.9 x 10 8 u/mg...
... C 25 H 27 N 2 NaO 7 ... Form: Dark burgundy metallic powder Identity: By IR ... 1 cm): greater than or equal to 60 ... than or equal to 10.0% lambda max ...
... the research-grade spectrofluorometer with a minimum 1 ... ratio 200 or greater for the Raman ... designed to keep in mind in order ... stopped-flow, titration, or anisotropic measurements. ,The FP-6500 ...
... Microarrays designed for genome-wide microRNA expression profiling ... Paraflo microfluidic on-chip synthesis platform. These microarrays ... microRNA Expression Profiling Service. Probe ... all known cow microRNAs (108 unique mature ...
Biology Products: